use
establish
nonhuman
primat
model
highli
pathogen
influenza
viru
infect
human
abl
demonstr
prophylact
mitig
pulmonari
damag
characterist
human
fatal
case
primari
influenza
viru
pneumonia
low
dose
oral
formul
commerci
avail
parenter
natur
human
interferon
alpha
alferon
n
inject
highest
oral
dose
iukg
bodi
weight
use
mark
reduct
alveolar
inflammatori
respons
minor
evid
alveolar
interstiti
edema
contrast
hemorrhag
inflammatori
respons
observ
alveoli
control
anim
mitig
sever
damag
lower
pulmonari
airway
observ
without
parallel
reduct
viral
titer
clinic
trial
data
necessari
establish
prophylact
human
efficaci
highli
pathogen
influenza
virus
abbrevi
hpai
highli
pathogen
avian
influenza
lpai
low
pathogen
avian
influenza
hpivh
highli
pathogen
influenza
viru
human
tlr
tolllik
receptor
ldo
low
dose
oral
ifn
interferon
protect
pulmonari
tissu
damag
associ
infect
cynomolgu
macaqu
highli
pathogen
avian
influenza
viru
low
dose
natur
human
ifna
administ
buccal
mucosa
highli
pathogen
avian
influenza
viru
endem
wild
bird
asia
middl
east
caus
diseas
high
lethal
transmiss
domest
poultri
infect
human
rel
rare
associ
high
mortal
rate
due
highli
alveolar
destruct
primari
viral
pneumonia
frequent
express
clinic
acut
respiratori
distress
syndrom
ard
abdelghafar
et
al
histopatholog
parallel
viral
pneumonia
associ
influenza
pandem
taubenberg
moren
high
viral
load
intens
inflammatori
respons
associ
hypercytokinemia
central
element
pathogenesi
human
de
jong
et
al
observ
high
mortal
human
prior
immunolog
memori
variou
current
avian
clade
highli
pathogen
influenza
viru
human
hpivh
remain
potenti
pandem
threat
low
pathogen
influenza
viru
recent
emerg
avian
influenza
viru
low
pathogen
poultri
gao
et
al
close
parallel
similar
human
pandem
potenti
moren
et
al
base
report
efficaci
follow
oral
administr
alferon
n
cummin
et
al
well
initi
microchip
evid
human
gene
modul
unpublish
studi
initi
determin
whether
experiment
low
dose
oral
formul
alferon
ldo
commerci
avail
natur
interferona
ifnaalferon
n
inject
could
modul
pathogenesi
hpivh
establish
nonhuman
primat
model
rimmelzwaan
et
al
alferon
n
significantli
higher
specif
activ
hiv
vsv
commerci
recombin
ifn
fan
et
al
compos
least
allel
encod
human
ifna
genecard
data
studi
demonstr
alferon
ldo
provid
protect
pulmonari
damag
observ
lethal
case
primari
hpivh
pneumonia
although
direct
effect
pulmonari
titer
observ
dose
administ
biohazard
experi
conduct
viroclin
bioscienc
bv
rotterdam
netherland
contract
hemispherx
biopharma
inc
philadelphia
pa
usa
base
initi
microarray
assay
mrna
peripher
blood
respons
human
three
alferon
ldo
treatment
group
iukg
bodi
weight
vehicl
citrat
buffer
control
group
randomli
establish
group
cynomolgu
macaqu
macaca
fasciculari
age
ca
month
bodyweight
kg
initi
day
dose
anim
obtain
hartelust
bv
tilburg
netherland
origin
guangxi
china
anim
visual
inspect
sign
ill
health
veterinarian
consid
healthi
use
studi
anim
hous
treatment
group
durat
studi
isol
cage
identifi
tattoo
bodyweight
record
daili
anim
offer
food
water
ad
libitum
light
control
give
h
h
dark
cycl
room
temperatur
humid
level
maintain
respect
dose
alferon
ldo
prepar
iuml
buffer
citrat
solut
commerci
alferon
n
titer
establish
nih
standard
within
one
hour
administr
alferon
ldo
iukg
ml
appli
oral
mucosa
anesthet
anim
ketamin
mgkg
dormitor
mgkg
inhibit
immedi
ingest
insur
least
min
exposur
buccal
mucos
target
site
daili
day
infect
establish
day
strain
intratrach
administr
tcid
ml
volum
use
viabl
viru
conduct
strict
bsliii
government
guidelin
oversight
prepar
administr
perform
bsliii
laboratori
bsliii
neg
pressur
glove
box
isol
cage
respect
viral
titer
establish
homogen
tissu
sampl
right
lung
frozen
necropsi
quantit
revers
transcript
qrtpcr
primer
deriv
conserv
region
matrix
gene
segment
describ
previous
fouchier
et
al
infect
assay
viru
titrat
madin
darbi
canin
kidney
mdck
cell
tcid
day
infect
follow
euthanasia
ketamin
anesthesia
macroscop
postmortem
examin
perform
anim
includ
examin
extern
surfac
thorac
abdomin
pelvic
caviti
associ
organ
tissu
neck
associ
organ
tissu
lung
lobe
left
cranial
lobe
cranial
caudal
segment
left
caudal
lobe
right
cranial
middl
caudal
lobe
accessori
lobe
inspect
lesion
describ
left
lung
collect
autopsi
inflat
intrabronchi
neutralbuff
formalin
store
fixationhistolog
microscop
examin
order
minim
type
ii
statist
error
due
small
number
macaqu
four
treatment
group
n
twotail
nonparametr
rank
order
jonckheereterpstra
test
jt
bewick
et
al
use
test
hypothesi
popul
mean
alferon
dose
order
respons
drug
function
dose
degre
sever
histopatholog
lesion
rank
follow
margin
slight
moder
mark
sever
gross
number
observ
lesion
use
establish
independ
rank
order
analysi
signific
observ
anatom
abnorm
function
alferon
ldo
dose
calcul
jt
statist
evalu
associ
probabl
valu
use
standard
normal
distribut
tabl
base
initi
observ
gene
modul
human
alferon
ldo
prophylact
administ
buccal
mucosa
dosag
group
cynomolgu
macaqu
plu
placebo
control
day
prior
intratrach
administr
tcid
strain
day
infect
anim
sacrif
ketamin
anesthesia
postmortem
examin
viral
titer
perform
well
weight
wbc
analys
treatment
placebo
group
lost
weight
cours
experiment
protocol
fig
wbc
respons
infect
treatment
highli
variabl
observ
trend
data
shown
tabl
summar
pulmonari
viral
titer
day
follow
infect
inhibit
viral
replic
function
alferon
ldo
determin
qrtpcr
viral
infect
assay
gross
microscop
examin
lung
howev
reveal
compel
morpholog
evid
dose
depend
mitig
primari
atyp
pneumonia
tissu
damag
associ
human
morbid
mortal
avian
hpaiv
major
site
hpivh
replic
nonhuman
primat
model
use
studi
lung
result
sever
viral
primari
atyp
pneumonia
fig
b
illustr
repres
sever
histopatholog
lesion
placebo
control
anim
day
infect
induc
lesion
character
hemorrhag
mark
inflammatori
respons
neutrophil
lymphocyt
alveolar
edema
interstiti
edema
emphysema
destruct
alveolar
septa
administr
higher
dose
alferon
ldo
result
reduct
sever
gross
histopatholog
lesion
challeng
day
infect
fig
f
repres
induc
histopatholog
lesion
decreas
sever
alferon
ldo
dose
depend
area
pneumonia
margin
sever
seen
iukg
dose
level
illustr
fig
mark
reduct
inflammatori
respons
minor
element
alveolar
interstiti
edema
inflamm
alveoli
intact
minim
evid
inflammatori
respons
gross
patholog
consist
microscop
analysi
lung
placebo
anim
day
post
viru
challeng
exhibit
multipl
area
punctat
diffus
dark
red
area
pulmonari
surfac
consist
microscop
inflammatori
respons
alveolar
hemorrhag
observ
studi
consist
anatom
lesion
observ
origin
descript
model
rimmelzwaan
et
al
macroscop
lesion
type
found
iukg
dose
group
gross
evid
adhes
fibrin
pleuriti
observ
placebo
iukg
treatment
group
microscop
evid
fibrin
pleuriti
observ
treatment
group
element
characterist
primari
viral
atyp
pneumonia
group
rank
base
aggreg
gross
tabl
histopatholog
sever
tabl
evalu
differ
sever
group
twosid
jonckheereterpstra
test
gross
patholog
function
alferon
ldo
dose
consist
microscop
evalu
two
anim
iukg
group
demonstr
evid
infect
gross
anatom
examin
similarli
dose
depend
reduct
quantit
sever
microscop
lesion
statist
signific
caudal
lobe
p
primari
viral
pneumonia
less
sever
cranial
lobe
yield
less
discrimin
treatment
highest
dose
level
alferon
ldo
iukg
demonstr
greatest
protect
macroscop
histopatholog
lesion
associ
infect
evalu
oral
natur
human
ifna
prophylact
inhibitor
pulmonari
damag
primari
pneumonia
establish
nonhuman
primat
model
infect
human
use
standard
evalu
protocol
gross
microscop
evalu
morpholog
evid
mitig
primari
lesion
associ
human
mortal
infect
observ
face
continu
viral
replic
day
infect
prophylact
daili
shortterm
administr
buccal
mucosa
low
dose
form
approv
parenter
human
ifna
alferon
n
inject
studi
influenza
viru
infect
mice
demonstr
viral
induc
cytokin
storm
associ
proteas
activ
damag
endotheli
tight
junction
result
lethal
pulmonari
edema
wang
et
al
associ
support
observ
mice
hypercytokinemia
sever
influenza
link
mark
upregul
cellular
trypsin
matrix
variou
organ
cell
particularli
endotheli
cell
result
vascular
hyperperm
multiorgan
failur
kido
et
al
among
potenti
mechan
mitig
pulmonari
injuri
primat
model
face
activ
pulmonari
replic
differenti
regul
ifna
induc
gene
function
ifna
buccal
mucosa
administr
concentr
type
ifn
induc
approxim
ifnstimul
gene
isg
wide
varieti
antivir
antigrowth
immunomodulatori
activ
sadler
william
disassoci
antivir
activ
pulmonari
protect
infect
achiev
low
dose
alferon
ldo
administr
via
buccal
mucos
rout
remain
unexplain
one
possibl
mechan
differenti
induct
isg
provid
protect
pulmonari
tissu
destruct
fail
induc
suffici
antivir
relat
isg
inhibit
replic
sever
recent
studi
provid
framework
futur
investig
hypothesi
schmeisser
et
al
demonstr
differenti
antivir
antiprolif
activ
isg
isg
restrict
antivir
effect
moreov
uniqu
set
isg
target
specif
virus
isg
paradox
promot
viral
prolifer
schoggin
et
al
virus
evolv
varieti
mechan
evad
isg
protein
control
number
cellular
function
infect
implic
abrog
antivir
gene
express
includ
nfjb
activ
ifnab
induct
bind
dsrna
wang
et
al
ctermin
epsev
sequenc
postul
potenti
virul
factor
bind
pdz
domain
protein
obenau
et
al
pdz
domain
function
scaffold
protein
coordin
supramolecular
complex
involv
intracellular
signal
function
sheng
sala
pdz
protein
common
target
mani
pathogen
virus
interf
tight
junction
format
establish
cell
polar
apoptosi
javier
rice
one
isg
may
function
pdz
domain
protein
serv
molecular
decoy
similarli
cytokin
storm
postul
respons
part
lethal
well
respons
seriou
outcom
infect
season
influenza
viru
elderli
immunocompromis
popul
butler
differenti
regul
isg
protein
one
member
tnfa
famili
provid
altern
mechan
observ
disassoci
antivir
activ
pulmonari
protect
observ
alferon
ldo
viru
nonhuman
primat
anim
model
infect
although
ifn
physiolog
activ
picomolar
rang
ifn
tradit
administ
massiv
concentr
subcutan
intramuscular
intralesion
inject
matzing
et
al
demonstr
induct
isg
follow
system
mucos
administr
recombin
pegyl
ifna
rhesu
macaqu
associ
reduct
tracheal
viral
titer
system
respons
fever
bodi
weight
follow
infect
substanti
bodi
literatur
support
antivir
activ
oral
ifn
comprehens
review
cummin
et
al
bulk
report
varieti
anim
speci
includ
human
indic
efficaci
respons
oral
administr
low
dose
ifn
wide
varieti
indic
initi
regulatori
approv
ldoifna
grant
japan
treatment
rotaviru
diseas
calv
day
age
intranas
administr
ferret
ifna
result
reduc
morbid
infect
surviv
challeng
howev
affect
kugel
et
al
control
studi
human
low
dose
ifna
oral
nasal
agent
season
influenza
support
clinic
trial
alferon
ldo
prophylact
agent
viru
infect
solovev
report
highli
efficaci
respons
season
influenza
viru
infect
intranas
administr
human
ldoifna
adult
p
children
p
soviet
union
studi
use
nasal
spray
u
oral
form
u
reduc
length
symptom
jordan
et
al
subsequ
studi
children
bulgaria
report
prevent
rate
season
upper
respiratori
infect
nasal
ifna
formul
arnaoudova
et
al
dai
et
al
use
combin
nasalor
administr
low
dose
ifna
day
bid
reduc
length
symptom
season
upper
respiratori
infect
econom
human
consequ
influenza
pandem
high
lethal
human
without
effect
counter
measur
signific
recent
structur
studi
demonstr
avian
sialic
receptor
cone
shape
deni
access
human
configur
tharakaraman
et
al
tharakaraman
et
al
human
receptor
open
umbrella
v
cone
allow
access
sialiat
glycan
clade
singl
amino
acid
mutat
high
affin
bind
kd
pm
similar
pandem
current
one
mutat
allow
open
confirm
high
affin
bind
develop
vaccin
direct
rel
rapid
although
high
protein
dosag
level
appar
lack
cross
clade
protect
problem
report
similar
low
antigen
moreov
tharakaraman
et
al
identifi
sever
coevolv
amino
acid
site
appear
antigen
region
prepandrix
low
dose
inactiv
split
vaccin
adjuv
proprietari
glaxo
smith
kline
oilinwat
prepar
report
achiev
signific
cross
clade
protect
ferret
bara
et
al
altern
nasal
prepar
season
vaccin
japan
adjuv
tolllik
receptor
tlr
agonist
provid
crossclad
protect
mice
ichinoh
et
al
absent
broadli
protect
vaccin
current
antivir
control
depend
agent
approv
use
neuraminidas
inhibitor
agent
deriv
current
approv
use
regulatori
approv
quickli
navig
ldoifna
use
studi
report
drug
approv
parenter
use
human
much
higher
concentr
multispeci
glycosyl
natur
ifna
product
broad
antivir
activ
includ
oseltamivir
resist
liu
et
al
experienc
develop
antiifn
antibodi
associ
recombin
nonglycosyl
ifn
clinic
use
strayer
carter
precis
mechan
observ
protect
pulmonari
tissu
damag
virusinduc
primari
atyp
pneumonia
establish
nonhuman
primat
model
highli
pathogen
human
hpivh
unknown
studi
age
macaqu
suggest
differenti
respons
age
young
adult
macaqu
infect
coronaviru
respons
sever
acut
respiratori
syndrom
sarscov
relat
zealou
inflammatori
gene
activ
respons
viral
infect
age
anim
associ
reduct
express
ifn
smit
et
al
similar
studi
treatment
ifn
reduc
pulmonari
patholog
without
reduc
sarscov
replic
lung
develop
ldoifna
anim
human
may
provid
readili
avail
oral
administ
econom
sourc
effect
prophylact
hpivh
pulmonari
tissu
damag
well
indic
sar
andor
mer
similar
pulmonari
patholog
gu
korteweg
wmm
wac
member
board
director
hemispherx
biopharma
inc
public
compani
wac
dr
employ
hemispherx
wmm
wac
dr
sharehold
compani
fund
hemispherx
biopharma
inc
